Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma

Georgina Long • 29 Sep 2019
ESMO 2019
Melanoma Skin Cancer Ipilimumab Nivolumab
OpACIN-neo

Georgina Long, MD, PhD, FRACP, from the University of Sydney, Sydney, Australia, explains the 18-month relapse-free survival and biomarker analyses from the OpACIN-neo trial (NCT02977052). This trial aims to identify the optimal dosing schedule of neoadjuvant ipilimumab and nivolumab in stage III melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Georgina Long

0:56
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Georgina Long • 10 Sep 2022
0:36
Challenges associated with implementing ctDNA approaches in melanoma
Georgina Long • 10 Sep 2022
2:01
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma
Georgina Long • 10 Sep 2022
1:20
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
Georgina Long • 10 Sep 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals